Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.

SRX246 is a potent, highly selective human vasopressin V1a antagonist that crosses the blood-brain barrier in rats. CNS penetration makes SRX246 an ideal candidate for potential radiolabeling and use in visualization and characterization of the role of the V1a receptor in multiple stress-related disorders. Before radiolabeling studies, cold reference analogs of SRX246 were prepared. This study describes the synthesis and in vitro screening for human V1a receptor binding and permeability of fluoro, iodo, and methyl reference compounds for SRX246 and the preparation of a tin precursor. For each compound, the potential utility of corresponding radiolabeled analogs for PET and SPECT imaging is discussed.

[1]  D. Swaab,et al.  Increased Arginine Vasopressin mRNA Expression in the Human Hypothalamus in Depression: A Preliminary Report , 2006, Biological Psychiatry.

[2]  P. Joyce,et al.  Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine , 2001, Psychopharmacology.

[3]  F. Holsboer,et al.  V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[4]  Larry J Young,et al.  Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice , 2004, Neuropsychopharmacology.

[5]  H. Anisman,et al.  Corticotropin-Releasing Hormone, Arginine Vasopressin, Gastrin-Releasing Peptide, and Neuromedin B Alterations in Stress-Relevant Brain Regions of Suicides and Control Subjects , 2006, Biological Psychiatry.

[6]  H. Coenen,et al.  Nucleophilic 18F-fluorination of heteroaromatic iodonium salts with no-carrier-added [18F]fluoride. , 2007, Journal of the American Chemical Society.

[7]  O. Solin,et al.  Radiosynthesis and evaluation of [18F]Selectfluor bis(triflate). , 2010, Angewandte Chemie.

[8]  Li Di,et al.  High throughput artificial membrane permeability assay for blood-brain barrier. , 2003, European journal of medicinal chemistry.

[9]  J. Maffrand,et al.  Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. , 2002, Progress in brain research.

[10]  Gary W. Caldwell,et al.  Optimization In Drug Discovery In Vitro Methods , 2010 .

[11]  T. Dinan,et al.  Vasopressin as a target for antidepressant development: an assessment of the available evidence. , 2002, Journal of affective disorders.

[12]  D. Swaab,et al.  Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. , 1996, Archives of general psychiatry.

[13]  A. Konings.  FREE-RADICAL PATHOLOGY - AN INTRODUCTION , 1987 .

[14]  R. Derijk,et al.  Anxious–Retarded Depression: Relation with Plasma Vasopressin and Cortisol , 2003, Neuropsychopharmacology.

[15]  R. Landgraf,et al.  Born to be Anxious: Neuroendocrine and Genetic Correlates of Trait Anxiety in HAB Rats , 2003, Stress.

[16]  I. Greguric,et al.  Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. , 2007, Journal of medicinal chemistry.

[17]  N. Toschi,et al.  Reduction of Hypothalamic Vasopressinergic Hyperdrive Contributes to Clinically Relevant Behavioral and Neuroendocrine Effects of Chronic Paroxetine Treatment in a Psychopathological Rat Model , 2003, Neuropsychopharmacology.

[18]  M. Timsit-Berthier,et al.  [Study of the stress response: role of anxiety, cortisol and DHEAs]. , 2002, L'Encephale.

[19]  T. Insel,et al.  Facilitation of Affiliation and Pair-Bond Formation by Vasopressin Receptor Gene Transfer into the Ventral Forebrain of a Monogamous Vole , 2001, The Journal of Neuroscience.

[20]  B. Långström,et al.  Synthesis of 3-[(2S)-azetidin-2-ylmethoxy]-5-[11C]-methylpyridine, an analogue of A-85380, via a Stille coupling , 2002 .

[21]  P. Veinante,et al.  Vasopressin and Oxytocin Excite Distinct Neuronal Populations in the Central Amygdala , 2005, Science.

[22]  B. Faller,et al.  High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. , 2001, Journal of medicinal chemistry.

[23]  Nicolas Singewald,et al.  A Hypomorphic Vasopressin Allele Prevents Anxiety-Related Behavior , 2009, PloS one.

[24]  C. Nemeroff,et al.  Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. , 1998, The Psychiatric clinics of North America.

[25]  F. Holsboer,et al.  Endocrine disturbances in depression , 2005, Journal of endocrinological investigation.

[26]  G. Kerkhof,et al.  Weak 24-h periodicity of body temperature and increased plasma vasopressin in melancholic depression , 2001, European Neuropsychopharmacology.

[27]  Gary W. Caldwell,et al.  Optimization in Drug Discovery , 2014, Methods in Pharmacology and Toxicology.

[28]  D. Rujescu,et al.  Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: Focus on vasopressin and glyoxalase-I , 2007, Neuroscience & Biobehavioral Reviews.

[29]  J. Hooker,et al.  Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography. , 2010, Bioorganic & medicinal chemistry letters.

[30]  S. Volpi,et al.  Vasopressinergic Regulation of the Hypothalamic Pituitary Adrenal Axis and Stress Adaptation , 2004, Stress.

[31]  R. Landgraf.  The involvement of the vasopressin system in stress-related disorders. , 2006, CNS & neurological disorders drug targets.

[32]  C. Ferris,et al.  Azetidinones as vasopressin V1a antagonists. , 2007, Bioorganic & medicinal chemistry.

[33]  F. Zufall,et al.  Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task , 2004, Hormones and Behavior.

[34]  K. Zwinderman,et al.  Depression with above-normal plasma vasopressin: Validation by relations with family history of depression and mixed anxiety and retardation , 2006, Psychiatry Research.

[35]  N. Meanwell.  Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.

[36]  T. Dinan,et al.  Anatomy of melancholia: focus on hypothalamic–pituitary–adrenal axis overactivity and the role of vasopressin , 2005, Journal of anatomy.

[37]  R. Ring.  The central vasopressinergic system: examining the opportunities for psychiatric drug development. , 2005, Current pharmaceutical design.

[38]  S. Adelstein,et al.  [125I/127I]iodoHoechst 33342: synthesis, DNA binding, and biodistribution. , 1996, Journal of medicinal chemistry.

[39]  Praveen Kulkarni,et al.  Imaging the neural circuitry and chemical control of aggressive motivation , 2008, BMC Neuroscience.

[40]  C. Ferris,et al.  Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior , 2006, Pharmacology Biochemistry and Behavior.

[41]  F. Holsboer,et al.  Glucocorticoids and depression. , 1999, Bailliere's best practice & research. Clinical endocrinology & metabolism.

[42]  V. Wiegant,et al.  Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression , 1997, Neuropsychopharmacology.

[43]  M. Thibonnier,et al.  Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. , 1994, The Journal of biological chemistry.

[44]  Shuiyu Lu,et al.  Fast and high-yield microreactor syntheses of ortho-substituted [(18)F]fluoroarenes from reactions of [(18)F]fluoride ion with diaryliodonium salts. , 2010, The Journal of organic chemistry.

[45]  F. Holsboer,et al.  Alterations in Central Neuropeptide Expression, Release, and Receptor Binding in Rats Bred for High Anxiety: Critical Role of Vasopressin , 2004, Neuropsychopharmacology.

[46]  C. Wotjak,et al.  Septal vasopressin modulates anxiety-related behaviour in rats , 1996, Neuroscience Letters.

[47]  Dennis K. Taylor,et al.  1,2-dioxines containing tethered hydroxyl functionality as convenient precursors for pyran syntheses. , 2005, The Journal of organic chemistry.